Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Regeneron Pharmaceuticals Inc.
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of[...]
Title and Summary Summary ToggleSynaptics Incorporated Prices $400.0[...]
11/15/2024 | Press release | Distributed by Public on 11/14/2024 21:36
Please select the service you want to use:
Smartlinks | Vaxart Inc. | News | Health | Science | Research | Finance | Security Markets | Security Markets | Company News | Top Company News | Corporate Debt | Pharmaceuticals | Securities Issuers | Biotechnology and Medical Research Companies | Frankfurt Stock Exchange | Berlin Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | Tradegate Exchange | NYSE American | NYSE ARCA Equities | Nasdaq Capital Market | Cboe BZX Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Bolsa Institucional de Valores (BIVA) | Nasdaq BX | Nasdaq PSX | NYSE Chicago
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact